ArticleAntimicrobial agents and chemotherapy2015
Antimicrobial activity against intraosteoblastic Staphylococcus aureus.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesPooled it
- A multicenter randomized placebo controlled trial of rifampin to reduce pedal amputations for osteomyelitis in veterans with diabetes (VA INTREPID).BMC infectious diseases · 2020Trial
- Establishment of a human osteocyte model to reveal mechanisms of chronic Staphylococcus epidermidis bone and joint infections.Bone & joint research · 2026Article
- Evaluating the efficacy of delafloxacin and combination therapy against Staphylococcus aureus Biofilms: insights into activity in acidic environments.Scientific reports · 2026Article
- Small-colony variants of Staphylococcus aureus: hidden threat in chronic and recurrent infections.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Article
- A methodological approach to improve extracellular staphylococcal clearance in internalization assays using bone-associated host-cell models of orthopedic infections.Frontiers in cellular and infection microbiology · 2026Article
- Intracellular survival ofVirulence · 2025Review
- Evaluation of clindamycin use in bone and joint infections: is monotherapy a safe option? A monocentric observational study 2014-19.JAC-antimicrobial resistance · 2025Article
- Monitoring intracellular replication dynamics unveils high proportion of non-replicating antibiotic-tolerant Staphylococcus aureus inside osteoblasts.PLoS pathogens · 2025Article
- Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review.Microorganisms · 2025Review
- Article
- [Role of antibiotic delivery system targeting bacterial biofilm based on ε-poly-Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2025Article
- Implant-DerivedAntibiotics (Basel, Switzerland) · 2025Article
- The impact of rifampin on the efficacy of implant retention and prosthesis removal in staphylococcal periprosthetic joint infection.Frontiers in cellular and infection microbiology · 2025Article
- Chondrocyte Invasion May Be a Mechanism for Persistent Staphylococcus Aureus Infection In Vitro.Clinical orthopaedics and related research · 2024Article
- Debridement, Antibiotics, and Implant Retention for a Rare Serratia marcescens Infection after Total Knee Arthroplasty: A Case Report.Journal of orthopaedic case reports · 2024Article
- Shock wave assisted intracellular delivery of antibiotics against bone infection withJournal of orthopaedic translation · 2024Article
- The Controversial Effect of Antibiotics on Methicillin-SensitiveInternational journal of molecular sciences · 2023Article
- Reliability of E-Tests and the Phoenix Automated Method in Assessing Susceptibility to IV Fosfomycin-Comparative Studies Relative to the Reference Method.Pathogens (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although Staphylococcus aureus persistence in osteoblasts, partly as small-colony variants (SCVs), can contribute to bone and joint infection (BJI) relapses, the intracellular activity of antimicrobials is not currently considered in the choice of treatment strategies for BJI. Here, antistaphylococcal antimicrobials were evaluated for their intraosteoblastic activity and their impact on the intracellular emergence of SCVs in an ex vivo osteoblast infection model. Osteoblastic MG63 cells were infected for 2 h with HG001 S. aureus. After killing the remaining extracellular bacteria with lysostaphin, infected cells were incubated for 24 h with antimicrobials at the intraosseous concentrations reached with standard therapeutic doses. Intracellular bacteria and SCVs were then quantified by plating cell lysates. A bactericidal effect was observed with fosfomycin, linezolid, tigecycline, oxacillin, rifampin, ofloxacin, and clindamycin, with reductions in the intracellular inocula of -2.5, -3.1, -3.9, -4.2, -4.9, -4.9, and -5.2 log10 CFU/100,000 cells, respectively (P < 10(-4)). Conversely, a bacteriostatic effect was observed with ceftaroline and teicoplanin, whereas vancomycin and daptomycin had no significant impact on intracellular bacterial growth. Ofloxacin, daptomycin, and vancomycin significantly limited intracellular SCV emergence. Overall, ofloxacin was the only molecule to combine an excellent intracellular activity while limiting the emergence of SCVs. These data provide a basis for refining the choice of antibiotics to prioritise in the management of BJI, justifying the combination of a fluoroquinolone for its intracellular activity with an anti-biofilm molecule, such as rifampin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.